Norovirus is the leading cause of gastroenteritis and is responsible for hundreds of thousands of deaths every year. However, ...

A new reverse genetics system for norovirus could aid in the development of novel antiviral therapies and vaccines.

Researchers from The University of Osaka have developed a novel reverse genetics system to study norovirus, the leading cause of gastroenteritis. This efficient system can generate infectious viral ...

Arexvy is GSK’s adjuvanted recombinant vaccine designed to prevent lower respiratory tract disease (LRTD) caused by RSV. Initially approved for adults aged 60 and older, as well as those aged 50-59 ...

EMA committee recommends approval of GSK’s RSV vaccine, Arexvy for all adults 18 years and older: London, UK Saturday, December 13, 2025, 13:00 Hrs [IST] GSK plc announced that ...

The recombinant zoster vaccine (Shingrix) was associated with a 17% increase in time without a dementia diagnosis, compared with the live vaccine. This translated into 164 additional days without a ...

The UKHSA has detected an inter-clade recombinant mpox virus in England; vaccines remain effective and risk to the public is ...

RSV, and influenza show continued safety and substantial effectiveness against hospitalization across various populations.